Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% on Tuesday . The stock traded as low as $12.92 and last traded at $12.92. 987 shares traded hands during trading, a decline of 99% from the average session volume of 175,869 shares. The stock had previously closed at $13.46.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on RPTX shares. HC Wainwright lowered their price objective on Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, November 17th. Capital One Financial restated an "overweight" rating and set a $28.00 price target on shares of Repare Therapeutics in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $30.80.
Get Repare Therapeutics alerts:Repare Therapeutics Price Performance
The business's 50-day moving average price is $15.50 and its 200 day moving average price is $13.94.
Repare Therapeutics (NASDAQ:RPTX – Get Rating) last posted its earnings results on Wednesday, November 9th. The company reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $1.91. The business had revenue of $112.55 million for the quarter, compared to analysts' expectations of $43.23 million. Repare Therapeutics had a negative net margin of 21.31% and a negative return on equity of 9.53%. On average, analysts predict that Repare Therapeutics Inc. will post -0.69 EPS for the current fiscal year.Insider Buying and Selling
In other Repare Therapeutics news, Director Davis Jerel sold 250,000 shares of the firm's stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $16.00, for a total value of $4,000,000.00. Following the sale, the director now owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 30.30% of the stock is owned by company insiders.
Institutional Trading of Repare Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fred Alger Management LLC increased its stake in Repare Therapeutics by 6.8% in the third quarter. Fred Alger Management LLC now owns 24,311 shares of the company's stock valued at $295,000 after acquiring an additional 1,539 shares during the last quarter. State Street Corp raised its stake in shares of Repare Therapeutics by 1.2% during the third quarter. State Street Corp now owns 53,475 shares of the company's stock worth $649,000 after acquiring an additional 648 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Repare Therapeutics in the 3rd quarter valued at $344,000. Trexquant Investment LP grew its holdings in shares of Repare Therapeutics by 55.5% during the 3rd quarter. Trexquant Investment LP now owns 79,674 shares of the company's stock valued at $966,000 after purchasing an additional 28,447 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Repare Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 73,842 shares of the company's stock worth $895,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 78.19% of the company's stock.
About Repare Therapeutics
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Featured Articles
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
- Skechers Not Nike Is The Sneaker Stock to Own for 2023
- Can The Rally In e.l.f. Beauty Stock Continue?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.